They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

TD Cowen had upgraded Merck in early 2024 based on confidence in Keytruda and Gardasil’s performance, a lack of binary risks, and an attractive valuation. However, setbacks in Gardasil’s China sales ...

Big pharma has come under a lot of scrutiny from regulators and consumers as sentiment sours on the industry. As such, the ...

TD Cowen has downgraded Merck (NYSE:MRK) to hold from buy, citing Keytruda's impending loss of market exclusivity, or LOE. The bank said it no longer sees "viable arguments" for outperformance in the ...

We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look at where Merck & Co., Inc.

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Merck, known as MSD outside the US and Canada, got approval for Vaxneuvance from the FDA in July – a month after Pfizer upped the ante in the competitive stakes with a green light for Prevnar-20 ...